735351-47-0

Basic information

• Product Name: Benzoic acid, 4-nitro-2-(2-propenyloxy)-, 2-propenyl ester
• CAS NO: 735351-47-0
• Molecular Formula: C13H13NO5
• Molecular Weight: 263.25
• Mol File: 735351-47-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-nitro-2-(2-propenyloxy)-, 2-propenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-nitro-2-(2-propenyloxy)-, 2-propenyl ester(735351-47-0)
• EPA Substance Registry System: Benzoic acid, 4-nitro-2-(2-propenyloxy)-, 2-propenyl ester(735351-47-0)

Safety Data

• Hazardous Substances Data: 735351-47-0(Hazardous Substances Data)

Upstream product

• 619-19-2 2-hydroxy-4-nitrobenzoic acid 
• 106-96-7 propargyl bromide 
• 106-95-6 allyl bromide 

Downstream Products

• 735351-48-1 2-(allyloxy)-4-nitrobenzoic acid 

Relevant articles and documents

Preparation and application of novel CDK9 inhibitor with macrocyclic skeleton structure

The invention discloses a preparation method and application of a novel CDK9 inhibitor with a macrocyclic skeleton structure, which can effectively inhibit CDK9 protein activity and has good CDK9 selectivity. The invention also discloses a preparation met

ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS

The present invention relates to a antibiotically active compounds characterized by general formula (I), wherein X1, BB, BC, BD, BE and X2 are building blocks with D1, D2, D3, D4 or D5 being linkers which comprise carbon, sulphur, nitrogen, phosphor and/or oxygen atoms and which are covalently connecting the moities BA and BB, BB and BC, BC and BD, BD and BE and BE and BF, respectively, and wherein in particular the building block BC comprises an amino acid derivative. The invention relates further to said compounds for use in a method of treatment of diseases, in particular for use in a method of treatment of bacterial infections.

AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1

Compounds of the formula (I) provide pharmacological agents which lower intracellular glucocorticoid concentrations in mammals, in particular, intracellular cortisol levels in humans. Therefore, the compounds of the instant invention improve insulin sensitivity in the muscle and the adipose tissue, and reduce lipolysis and free fatty acid production in the adipose tissue. The compounds of the invention lower hepatic glucocorticoid concentration in mammals, in particular, hepatic cortisol concentration in humans, resulting in inhibition of hepatic gluconeogenesis and lowering of plasma glucose levels. Thus, the compounds of the instant invention may be particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which hyperglycemia and/or insulin resistance are implicated, such as type-2 diabetes. The compounds of the invention may also be used to treat other glucocorticoid associated disorders, such as Syndrome-X, dyslipidemia, hypertension and central obesity. The invention furthermore relates to the use of the compounds according to the invention for the preparation of medicaments, in particular of medicaments useful for the treatment and prevention of glucocorticoid associated disorders, by improving insulin sensitivity, reducing plasma glucose levels, reducing lipolysis and free fatty acid production, and by decreasing visceral adipose tissue formation.